Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Akeso Biopharma Co., Ltd.
CRL
•Akeso Biopharma Co., Ltd.

Akeso Biopharma Co., Ltd. – FDA CRL

Record Details

The FDA issued a Complete Response Letter (CRL) to Akeso Biopharma Co., Ltd. regarding its Biologics License Application (BLA 761258) for penpulimab-kcqx (AK105), indicating the application cannot be approved in its present form. Key issues were identified across clinical, product quality, and manufacturing facility compliance following a pre-license inspection (PLI) at Akeso's facility in Zhongshan, China.

Clinically, the FDA determined that results from Study AK105-202 for metastatic nasopharyngeal carcinoma (NPC) did not demonstrate a meaningful advantage over currently available therapies, failing to meet accelerated approval criteria under 21 CFR 601.41. The agency recommends a new multiregional randomized clinical trial with progression-free and overall survival endpoints, ensuring diverse U.S. patient representation, including adolescents.

Product quality deficiencies, cited under 21 CFR 601.20(c), included the lack of a qualified cell bank for sustained commercial supply, inadequate quality control methods, and insufficient data to support drug product manufacturing process control ranges. Akeso must provide extensive data for cell bank qualification, optimize and validate QC methods, and substantiate process control ranges.

Unresolved deficiencies from the PLI at the manufacturing facility also require satisfactory responses, with a potential for re-inspection. Additionally, a comprehensive safety update and specific labeling revisions, including adding a Medication Guide statement per 21 CFR 208.24(d), are required.

Company
Akeso Biopharma Co., Ltd.
Product type
BLA
Person
  • Liang Liu (U.S. Agent)
View Company Profile

ID · dad1d4e2-44eb-40f3-884d-72e0320acf54

Other documents for Akeso Biopharma Co., Ltd.
  • 483 - 2025-03-04March 4, 2025
  • 483 - 2023-08-07August 7, 2023

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Akeso Biopharma Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.